Avalon Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Avalon Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15	Closed	-$6.04K	–	507
2024 Q4	$6.04K	Buy	+15	New	+$6.95K	﹤0.01%	347

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Avalon Trust's VRTX Position: Q1 2025 in Review

Avalon Trust sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 15 shares — an estimated $6.04K sold.

Avalon Trust first reported a position in VRTX in Q4 2024 and held it in 1 quarter. The position peaked at $6.04K in Q4 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Avalon Trust reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Avalon Trust sold 15 Vertex Pharmaceuticals shares in Q1 2025, an estimated $6.04K.
Avalon Trust first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Avalon Trust's Vertex Pharmaceuticals position peaked at $6.04K in Q4 2024.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Avalon Trust's 13F filing for Q1 2025, filed 9 May 2025.